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Abstract (196 words) 28 
 29 
Background: To investigate the performance and patient acceptability of an inhaler electronic 30 
monitoring device in a real-world childhood asthma population. 31 
 32 
Methods: Children 6 to 15 years presenting with asthma to the hospital emergency department and 33 
prescribed inhaled corticosteroids were included. Participants were randomized to receive a device 34 
with reminder features enabled or disabled for use with their preventer. Device quality control tests 35 
were conducted. Questionnaires on device acceptability, utility and ergonomics were completed at 36 
six months. 37 
 38 
Results: A total of 1306 quality control tests were conducted; 84% passed pre-issue and 87% return 39 
testing. The most common failure reason was actuation under-recording. Acceptability scores were 40 
high, with higher scores in the reminder than non-reminder group (median, 5th-95th percentile: 4.1, 41 
3.1-5.0 versus 3.7, 2.3-4.8; p<0.001). Most (>90%) rated the device easy to use. Feedback was 42 
positive across five themes: device acceptability, ringtone acceptability, suggestions for 43 
improvement, effect on medication use, and effect on asthma control. 44 
 45 
Conclusions: This study investigates electronic monitoring device performance and acceptability in 46 
children using quantitative and qualitative measures. Results indicate satisfactory reliability, 47 
although failure rates of 13-16% indicate the importance of quality control. Favorable acceptability 48 
ratings support the use of these devices in children. 49 
Keywords: Acceptability, adherence, asthma, children, devices, electronics 50 




1.0 Introduction  53 
Adherence to preventive therapy is essential for reducing morbidity in childhood asthma1, 2, yet 54 
adherence remains suboptimal3. Electronic monitoring devices (EMDs) are increasingly used to 55 
deliver adherence interventions and provide objective adherence data4, 5; but EMDs vary in their 56 
accuracy and reliability6-10 and there is little data available on patient acceptability11, 12. 57 
Implementation of standardized testing is recommended to evaluate the validity of EMD data 58 
collected, and measurement of patient-reported EMD acceptability is advised to identify feasibility 59 
issues13, 14. However, there is scant research on EMD performance and even fewer studies on patient 60 
acceptability in real world populations11, 15.  61 
The SmartTrack EMD (Adherium Limited Auckland, New Zealand; Figure 1) is an EMD for pressurized 62 
metered dose inhalers (pMDIs). This device has increasingly been used in adherence research4, 5, 11 as 63 
it has features that are not available on older EMDs, like the Doser14. These include remote data 64 
upload capability, real-time adherence feedback via an on-board screen and multiple customizable 65 
functions including customized reminder times and ringtones14. 66 
Whilst this device has been used in several published studies, there is currently little knowledge 67 
about its reliability in a real world setting or how patients respond to its use. In one 6-day study, 68 
SmartTrack actuation recording accuracy was reported at 99% and ease of use scores were high in 69 
adults with asthma11. A recent study investigated the attitudes of seven adolescents towards 70 
electronic monitoring after using the SmartTrack for 1 month, which showed generally positive 71 
attitudes to adherence monitoring12. There are however limited data on patient acceptability 72 
beyond these small studies, and no published data at all in children. The successful implementation 73 
of new health technologies is thought to depend on their acceptability by patients16, yet at present, 74 
little data exists on patient acceptability regarding EMDs11, 15, particularly in children6-10. 75 
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The SmartTrack EMD was recently used in a randomized controlled trial investigating the effects of a 76 
reminder EMD on adherence and asthma outcomes in 220 children aged 6 to 15 years presenting 77 
with an asthma exacerbation to the regional emergency department (ED) in Auckland, New Zealand 78 
4. We found there were significant improvements in adherence and asthma control. The objective of 79 
this paper is to assess the performance and patient acceptability of the SmartTrack EMD, when used 80 
in this six month trial. 81 
2.0 Patients and methods 82 
2.1 Patients and trial design 83 
This trial was undertaken in children aged 6 to 15 years, presenting with asthma to the regional ED in 84 
Auckland, New Zealand (Australian New Zealand Clinical Trials Registry no. ACTRN12613001353785). 85 
The full study design and methods are described in detail elsewhere4. All participants with a 86 
physician-diagnosis of asthma and prescribed regular, twice-daily inhaled corticosteroids were 87 
eligible. Exclusion criteria included diagnosis of chronic lung disease other than asthma, congenital 88 
heart disease, residence outside the Auckland area or diagnosis of a severe chronic medical 89 
condition leading to impaired immunity or increased morbidity4. All participants received the EMD 90 
attached to their preventer inhaler; half were randomized to receive the EMD with the reminder 91 
functions enabled (reminder group) and half disabled (non-reminder group). Each participant was 92 
followed up for six months. Face-to-face visits occurred every two months, where investigators 93 
collected the EMD for performance checking and data upload and participants completed 94 
questionnaires. Asthma control was assessed using the Asthma Morbidity Score17 and childhood 95 
Asthma Control Test18. Written informed consent was provided by the child’s parent or guardian, 96 
and written assent obtained from children. 97 
2.2 The electronic adherence monitoring device 98 
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Each SmartTrack EMD had an on-board reminder function which could be enabled or disabled by the 99 
investigators. When enabled, the EMD delivered twice-daily reminders for missed doses (Figure 1). 100 
Reminder times were set by investigators prior to each visit, as per participant preference. The 101 
reminder sounded until the correct dose was taken or for a maximum of fifteen minutes, and did not 102 
sound if the correct dose was taken in the six hours preceding the set reminder time. One of 103 
fourteen different ringtones played each time in a cyclical pattern. The EMD recorded the date and 104 
time of each actuation, ringtone initiation and sound, and pMDI or battery removal and insertion; 105 
this was stored until data upload. Adherence data was determined from these EMD records. The 106 
EMD battery compartment and pMDI entry door were secured using security screws to minimize 107 
participant tampering. 108 
Each participant was issued with an EMD at the first visit and shown how to use the device. The EMD 109 
was replaced at every visit. Participants were told that the study was investigating the effect of a 110 
reminder inhaler on asthma; the adherence monitoring function was not disclosed, as per 111 
established ethical guidelines19, to avoid interference with usual behavior. 112 
2.3 EMD quality control testing 113 
All devices were checked according to a standardized quality control (QC) procedure at two time 114 
points during the study: prior to issue to participants (‘pre-issue’ QC testing) and after return from 115 
participants (‘return’ QC testing) as described below and in the Supplemental Table S1 (online)14. 116 
Tests were carried out by one of three trained investigators. 117 
QC testing pass threshold 118 
Devices “passed” testing if all maneuvers were recorded with 100% event and time accuracy. At 119 
baseline an allowance of ±2 minutes was made for internal clock time drift, and ± 15 minutes after 120 
the two-monthly visits15. Reasons for QC test failure were documented and classified into categories. 121 
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Where more than one reason occurred, the primary reason for failure was reported. Affected 122 
devices were returned to the manufacturer for analysis, repair and data retrieval. 123 
‘Pre-issue’ QC testing 124 
QC tests were conducted in both reminder and non-reminder modes on each device. Pre-issue QC 125 
tests included checks for physical damage and functional and recording accuracy of actuations and 126 
reminders (Supplemental Table S1 (online)). Actuation recording accuracy was checked by actuating 127 
different numbers of puffs at different times of the day to mimic correct, over-, under- and zero 128 
dosing. Reminders were checked for accuracy of reminder timing, duration and response to under- 129 
and correct dosing. Investigators carried the EMD in pockets or bags in between active testing to 130 
mimic real life use. 131 
‘Return’ QC testing 132 
Return QC tests, similar to pre-issue tests (Supplemental Table S1 (online)), were carried out 133 
immediately after collecting the device from the participant to retain pre-return device conditions 134 
for accuracy checking of the device. Devices collected from the reminder group underwent a full 135 
return QC test; devices from the non-reminder group underwent a shorter return test, which 136 
omitted the reminder tests, as reminder testing was irrelevant. 137 
2.4 EMD acceptability and ringtone rating score 138 
Children completed a questionnaire about device acceptability at study end. The 7-item 139 
questionnaire was scored on a 5-point semantic differential scale (1=strongly disagree, 5=strongly 140 
agree) which asked about topics such as ease of use, usefulness for medication reminding, perceived 141 
effects on asthma control and device size.  Item 7 (using my new asthma inhaler in front of other 142 
people is embarrassing) was negatively worded. Participants using a reminder EMD completed an 143 
8th question asking how much they liked the reminder sounds and extra questions on ringtone 144 
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preference (14 ringtones were rated on a 4-point Likert scale (0 = very bad, 3 = very good)), device 145 
size (too big, just right, too small) and whether the device was easy to hold (yes, no). All 146 
questionnaires were completed by the child without assistance from the parent or caregiver. Where 147 
assistance was needed with interpretation and completion of the questionnaires, this was provided 148 
by the researcher. Children and caregivers could also provide written feedback about the device via 149 
a free-text comments field at the end of the paper questionnaire or through verbal feedback to the 150 
investigators either at or between visits via telephone. Feedback was optional. All written and verbal 151 
feedback were coded into themes by AC. The emergent themes were reviewed by AC and JMF; any 152 
discrepancies in the themes assigned were resolved by discussion. Ethics approval was obtained 153 
from the New Zealand Northern Y Regional Ethics Committee (NTY/08/12/116) and District Health 154 
Boards.  155 
2.5 Statistical analysis 156 
Descriptive statistics were calculated for patient demographics and acceptability scores. The mean 157 
number of faults per participant and acceptability scores were compared in reminder and non-158 
reminder patients using the Mann-Whitney U test. To determine whether there was any association 159 
between adherence and asthma control with acceptability scores for each item, univariate analyses 160 
were conducted using a general linear model with the variables as covariates. The Friedman test was 161 
used to compare ringtone ratings. P-values of less than 0.05 indicated statistical significance. 162 
Analyses were undertaken on the intention to treat population using IBM SPSS Statistics (version 163 
22)(IBM Corp, Armonk, NY, USA). 164 
3.0 Results 165 
As described previously4, of 656 patients initially identified as potentially eligible, 253 were ineligible 166 
on further assessment, 41 could not be contacted, 57 declined participation, 82 had already been 167 
assessed for eligibility and 3 excluded for other reasons. The remaining 220 participants were 168 
Page 9 
 
enrolled and 110 participants randomized to each group – the reminder EMD group versus the non-169 
reminder group. The participant flow diagram is shown in Figure 2, with baseline characteristics 170 
summarized in Table 1. 171 
3.1 EMD performance 172 
There were four categories of device failure (Table 2): data recording, reminder, battery or data 173 
upload faults. Pre-issue QC tests were conducted on 628 devices, of which 527 (84%) passed. The 174 
majority of failures were due to actuation recording inaccuracies (67%), followed by reminder faults 175 
(17%). 176 
During the study, 694 devices were issued (an average of three devices per participant; a new device 177 
at baseline, 2- and 4-month visits); 16 (2%) were not returned at study completion. Return QC 178 
testing was carried out on the remaining 678 devices, of which 591 (87%) passed. Of the 87 (13%) 179 
that failed, actuation recording inaccuracies accounted for the majority (95%) of failures. Physical 180 
damage was observed in four EMDs. The mean ± SD number of device faults per participant did not 181 
differ between the two groups (intervention: 0.45±0.79 versus control: 0.34±0.62; p=0.33). 182 
3.2 EMD acceptability, adherence and asthma control 183 
Ninety eight per cent (108/110) of participants in the reminder group and 95% (104/110) in the non-184 
reminder group completed the acceptability questionnaire. Median scores in both groups were high 185 
for most acceptability questions (medians 4 or higher) indicating that the majority were highly 186 
satisfied with the EMD (Table 3).  187 
A number of individual items were scored significantly higher in the reminder group including: ease 188 
of remembering (Reminder: median 5.0 (25th, 75th percentile: 4.0, 5.0) vs. non-reminder 4.0 (3.0, 189 
4.25); p<0.001) and knowing better when to take their asthma medication (Reminder: median 5.0 190 
(4.0, 5.0) vs. non-reminder 4.0 (3.0, 4.0); p<0.001). Patients who received reminders also reported 191 
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feeling more in control of their asthma (Reminder: 4.0 (4.0, 5.0) vs. non-reminder: 4.0 (3.0, 5.0), 192 
p=0.001). These improvements in perceived medication taking and perceived asthma control in the 193 
reminder group corresponded with actual improvements in objective measures of asthma control 194 
and adherence; the details of these results are reported elsewhere4. This is supported by the 195 
significant relationship seen between the statements “Knowing when to take my asthma medication 196 
is easy” and adherence (p<0.0005), and “I feel more in control of my asthma now” and the Asthma 197 
Morbidity Score and childhood Asthma Control Test (Appendices A1, A2 and A3). 198 
3.3 Ringtone ratings 199 
Of the 110 reminder EMD users, 104 (95%) completed the ringtone ratings questionnaire. There was 200 
a significant difference in the ratings of 14 different ringtones (χ2(13) = 185, P < 0.001). The highest 201 
ratings were for popular culture ringtones like “The Simpsons”, which had a median rating of 3 (25th-202 
75th percentile: 2-3). The lowest median ratings were for animal sound ringtones like “Donkey”, 203 
which received a rating of 2 (25th-75th percentile: 0.25-2).  204 
3.4 Device ergonomics 205 
One hundred of the 110 (91%) reminder EMD users completed the question on device handling, and 206 
99 (90%) completed the question on device size. Ninety four percent (94/100) agreed the device was 207 
easy to hold; 6% (6/100) disagreed. For device size, 81% (80/99) rated the device “just right”, 16% 208 
(16/99) “too big” and 3% (3/99) “too small”. 209 
3.5 Feedback about the EMD 210 
Verbal and written comments about the device were provided by 44 individuals (24 children, 20 211 
caregivers; 41 unique participant IDs). Of these individuals, 22 provided written, 21 verbal and 1 212 
both written and verbal comments. Feedback was coded into five themes: EMD acceptability, 213 
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ringtone acceptability, suggestions for EMD improvement, effect of EMD on medication use and 214 
effect of EMD on asthma control (Table 4).  215 
Some children reported finding the reminders intrusive due to ringtone type, volume, or reminder 216 
time but most responded favorably, describing reminders as helpful for medication taking. Many 217 
caregivers perceived improvements in their child’s asthma control as a result of EMD use. 218 
4.0 Discussion 219 
With an increase in EMD use in research, it is important to determine: a) if EMDs are feasible and 220 
practical for use in children, b) if EMDs can perform reliably in children over an extended period, and 221 
c) what unique factors need to be considered in this age group. We believe this is the first study to 222 
report on both EMD performance and quantitative and qualitative measures of patient acceptability 223 
of an EMD when used by children. The discussion below will focus on these two aspects – 224 
performance and acceptability – and the limitations of our study findings. Although the study 225 
specifically investigated the SmartTrack EMD in children presenting to the ED with asthma (i.e. a 226 
population at high-risk of non-adherence), these methods and results are likely applicable to other 227 
EMDs as well as other age groups when assessing an EMD for patient use. 228 
4.1 EMD performance 229 
Our QC failure rates were lower than previously reported in a SmartTrack validation study among 230 
adults (20–25%)11; but aligned with rates reported for other more established EMDs, such as the 231 
Doser (0-21%)9, 20, 21, MDIlog / Chronolog (10-53%)8, 9, 22, 23 and Smartinhaler (0-20%)15, 24, 25, and were 232 
within the maximum 10-20% failure rates considered feasible for research settings11. In the present 233 
study the SmartTrack EMD was used for longer and included more participants than the adult 234 
validation study11, thus likely providing more representative performance data. Further, the devices 235 
were used in children recruited from ED, providing the first acceptability data in a population whose 236 
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adherence and asthma control was poor26, 27, and where the device was challenged by real-life 237 
conditions, such as rough handling. In such populations, adherence monitoring may provide the 238 
most benefit, thus suggesting our performance results are generalizable to the population where 239 
EMDs are most needed4. 240 
4.2 Limitations – EMD performance  241 
Although the failure rate in children aligns with that of other available EMDs when used in adults, it 242 
remains a small but important percentage, which may need to be lower to encourage device 243 
implementation in clinical settings. Our requirement for 100% accuracy on all tested functions was 244 
exacting and may not have been necessary or realistic. At the start of the trial in 2010, the 245 
SmartTrack was a new device which lacked reported performance data; shorter tests may become 246 
more appropriate as reliable EMD performance data become available4, 5. 247 
4.3 EMD acceptability, adherence, and asthma control 248 
After six months of use, participants reported good acceptability for the EMD, including being willing 249 
to continue use (in both groups) and rating the reminder EMD favorably for medication reminding 250 
and knowing when to take medication. The reminder group also reported feeling significantly more 251 
in control of their asthma than participants without reminders. Improvements in perceived asthma 252 
control was reported both quantitatively via the EMD acceptability scale and qualitatively from 253 
participant feedback. The improvements in perceived control corresponds to data we have 254 
previously published4 on clinical asthma control in the same cohort; change from baseline in asthma 255 
control test scores at 6 months was significantly greater in the reminder group (BL: 18.8 (SD 4.5), 256 
6M: 22.7 (3.7)), compared with the non-reminder group (BL: 18.8 (4.2), 6M: 21.4 (4.2), p<0.0001). 257 
The improvements in perceived control thus mirrored the improvements seen from objective 258 
measures.  Of note, the EMD acceptability statements around asthma medication taking and asthma 259 
control corresponded with objective measures of adherence and asthma control respectively 260 
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(Appendices A1, A2 and A3).  The present results therefore suggest that a reminder EMD not only 261 
improves clinical asthma control, but it may correspondingly improve perceived asthma control 262 
(Table 3). This is important and signals further research, especially since greater perceived control of 263 
asthma has been associated with improved health status and decreased future risk of severe 264 
exacerbations requiring emergency healthcare utilization28. 265 
Ringtone ratings and device ergonomics 266 
Participants rated the ringtone options favorably, with a preference for popular culture ringtones, 267 
such as “The Simpsons”, and a lower preference for loud, abrupt or harsh ringtones, and animal 268 
sounds. Most (94%) rated the EMD as easy to hold and only a small proportion (16%) reported EMD 269 
size as “too big”. The large size of the SmartTrack EMD has been noted previously11, however EMDs 270 
are likely to become more compact with time. Indeed the re-branded version of the SmartTrack 271 
EMD (SmartTouch) appears to have addressed this by utilizing a smaller and softer casing14. EMD 272 
designers should consider these user preferences and ergonomic factors carefully when developing 273 
devices, particularly for use in children. 274 
4.4 Strengths and Limitations – EMD acceptability 275 
Previous research on EMD performance has focused predominantly on accuracy and reliability8, 13, 15, 276 
22, 24, 29 and lacks data on user acceptability, which is key to sustained patient use16. In the present 277 
study, we created a 7-item acceptability questionnaire which explored a variety of criteria, including 278 
attitudes to device use in public, responses to device features and ergonomic factors such as size 279 
and ease of handling. The questionnaire was designed such that it can be administered relatively 280 
quickly and easily to children.  Whilst this questionnaire was designed for the SmartTrack EMD and 281 
was answered by children, we specifically included questions generalizable to other EMDs and other 282 
age groups14 such as assessing satisfaction with continued use, effects on medication management 283 
and attitudes to use in public (Table 3). The ratings in the questionnaire were skewed, as is common 284 
Page 14 
 
to satisfaction rating scales30-32, and while distributional skew did not prevent the finding of 285 
statistical differences between the reminder and non-reminder groups, the magnitude of the 286 
difference between groups may have been underestimated.  Further, like the questionnaires used in 287 
the small acceptability studies carried out previously in adults and adolescents11, 12, our acceptability 288 
questionnaire was not validated. Young children can have difficulty comprehending the language 289 
used in questionnaires, and older children may refuse to complete questionnaires or provide 290 
inaccurate answers33. Although we report a high questionnaire completion rate (>95%), we cannot 291 
be certain that the questionnaire responses of younger children were not influenced by 292 
comprehension difficulties, though researchers assisted with comprehension where appropriate.  293 
Further validation testing of our questionnaire is recommended in a future acceptability study in 294 
children. 295 
5.0 Conclusions 296 
This study reports on both EMD performance and patient acceptability in children. Device 297 
performance was consistent with that of other EMDs, though there remains a small but important 298 
failure rate which needs to be addressed prior to use in a clinical setting. This study reinforces the 299 
practical approach and resources needed for QC testing and its key role for enhancing the integrity 300 
of adherence data. Using a combination of quantitative and open-text qualitative methods to 301 
explore patient acceptability, we found that the SmartTrack EMD was highly acceptable, highlighting 302 
the feasibility of its use in children. EMD use also positively affected attitudes toward adherence and 303 
perceptions of asthma control. Further research combining EMD reliability and acceptability 304 
assessments, including the influence of EMD use on perceptions of disease control, is recommended 305 
to ensure a wide and successful uptake of EMDs in research and clinical settings, and to increase our 306 
understanding of the role of EMDs in adherence interventions. 307 
Key issues: 308 
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- Electronic monitoring devices (EMDs) are increasingly used in adherence research and 309 
clinical practice 310 
- There is little information in the literature about the performance and acceptability of EMD 311 
use in children 312 
- This study reports on the performance and use of EMDs in children  313 
- EMDS were found to be highly acceptable in children 314 
- There was a small but significant failure rate of EMDs which will need to be addressed prior 315 
to implementation in routine practice  316 
- The study highlights the potential for use of EMDs in children 317 
 318 
  319 
Page 16 
 
6.0 References 320 
1. Bauman LJ, Wright E, Leickly FE, Crain E, Kruszon-Moran D, Wade SL, et al. Relationship of 321 
adherence to pediatric asthma morbidity among inner-city children. Pediatrics. 2002;110:e6. 322 
2. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. Relationship between 323 
adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin 324 
Immunol. 2004;114:1288-93. 325 
3. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Non-compliance and treatment 326 
failure in children with asthma. J Allergy Clin Immunol. 1996;98:1051-7. 327 
4. Chan AHY, Stewart AW, Harrison J, Camargo CA, Jr., Black PN, Mitchell EA. The effect of an 328 
electronic monitoring device with audiovisual reminder function on adherence to inhaled 329 
corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet 330 
Respir Med. 2015;3:210-19. 331 
5. Foster JM, Usherwood T, Smith L, Sawyer SM, Xuan W, Rand CS, et al. Inhaler reminders 332 
improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin 333 
Immunol. 2014;134:1260-68. 334 
6. Riekert KA, Rand CS. Electronic monitoring of medication adherence: when is high-tech best? 335 
J Clin Psychol Med S. 2002;9:25-34. 336 
7. Ingerski LM, Hente EA, Modi AC, Hommel KA. Electronic measurement of medication 337 
adherence in pediatric chronic illness: a review of measures. J Pediatr. 2011;159:528-34. 338 
8. Wamboldt F, Bender B, O'Connor SL, Gavin LA, Wamboldt MZ, Milgrom H, et al. Reliability of 339 
the model MC-311 MDI Chronolog. J Allergy Clin Immunol. 1999;104:53-7. 340 
9. Simmons MS, Nides M, Kleerup EC, Chapman KR, Milgrom H, Rand C, et al. Validation of the 341 
Doser, a new device for monitoring metered-dose inhaler use. J Allergy Clin Immunol. 1998;102:409-342 
13. 343 
10. Chan AHY, Reddel HK, Apter A, Eakin M, Riekert K, Foster JM. Adherence monitoring and e-344 
health: how clinicians and researchers can use technology to promote inhaler adherence in asthma. J 345 
Allergy Clin Immunol Pract. 2013;1:446-54. 346 
11. Foster JM, Smith L, Usherwood T, Sawyer SM, Rand CS, Reddel HK. The reliability and patient 347 
acceptability of the SmartTrack device: a new electronic monitor and reminder device for metered 348 
dose inhalers. J Asthma. 2012;49(6):657-62. 349 
12. Howard S, Lang A, Sharples S, Shaw D. See I told you I was taking it! Attitudes of adolescents 350 
with asthma towards a device monitoring their inhaler use: Implications for future design. Applied 351 
Ergonomics. 2017;58:224-37. 352 
13. Patel M, Pilcher J, Chan A, Perrin K, Black P, Beasley R. Six-month in vitro validation of a 353 
metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J 354 
Allergy Clin Immunol. 2012;130:1420-22. 355 
14. Chan AHY, Harrison J, Black PN, Mitchell EA, Foster JM. Using electronic monitoring devices 356 
to measure inhaler adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract. 357 
2015;3:335-49. 358 
15. Patel M, Pilcher J, Travers J, Perrin K, Shaw D, Black P, et al. Use of metered-dose inhaler 359 
electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin Immunol 360 
Pract. 2013;1:83-91. 361 
16. De Vito Dabbs A, Myers BA, Mc Curry KR, Dunbar-Jacob J, Hawkins RP, Begey A, et al. User-362 
Centered Design and Interactive Health Technologies for Patients. Comput Inform Nurs. 363 
2009;27(3):175. 364 
17. Mitchell E, Stewart A, Rea H, McNaughton S, Taylor G, Smith L, et al. Measuring morbidity 365 
from asthma in children. N Z Med J. 1997;110:3-6. 366 
Page 17 
 
18. Liu A, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development and cross-367 
sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007;119:817-25. 368 
19. Rand CS, Sevick MA. Ethics in adherence promotion and monitoring. Control Clin Trials. 369 
2000;21:S241-S7. 370 
20. O'Connor SL, Bender BG, Gavin-Devitt LA, Wamboldt MZ, Milgrom H, Szefler S, et al. 371 
Measuring adherence with the Doser CT in children with asthma. J Asthma. 2004;41:663-70. 372 
21. Bender B, Wamboldt FS, O'Connor SL, Rand C, Szefler S, Milgrom H, et al. Measurement of 373 
children's asthma medication adherence by self report, mother report, canister weight, and Doser 374 
CT. Ann Allergy Asthma Immunol. 2000;85:416-21. 375 
22. Brueckner JW, Sherman JM, Hendeles L. Reliability of the Medtrac MDI Chronolog. J Allergy 376 
Clin Immunol. 1997;100:488-91. 377 
23. Tashkin DP. Microelectronic adherence monitors for metered-dose inhalers: who monitors 378 
the monitors? J Allergy Clin Immunol. 1999;104:22-4. 379 
24. Burgess SW, Wilson SSI, Cooper DM, Sly PD, Devadason SG. In vitro evaluation of an asthma 380 
dosing device: the smart-inhaler. Respiratory medicine. 2006;100:841-5. 381 
25. Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, Rand CS, et al. 382 
Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. 383 
Intern Med J. 2012;42:136-44. 384 
26. Camargo CA, Jr., Ramachandran S, Ryskina KL, Lewis BE, Legorreta AP. Association between 385 
common asthma therapies and recurrent asthma exacerbations in children enrolled in a state 386 
Medicaid plan. Am J Health Syst Pharm. 2007;64:1054-61. 387 
27. Lafata JE, Xi H, Divine G. Risk factors for emergency department use among children with 388 
asthma using primary care in a managed care environment. Ambul Pediatr. 2002;2:268-75. 389 
28. Calfee CS, Katz PP, Yelin EH, Iribarren C, Eisner MD. The influence of perceived control of 390 
asthma on health outcomes. Chest. 2006;130(5):1312-8. 391 
29. Julius SM, Sherman JM, Hendeles L. Accuracy of three electronic monitors for metered-dose 392 
inhalers. Chest. 2002;121:871-6. 393 
30. Lin B, Kelly E. Methodological issues in patient satisfaction surveys. Int J Health Care Qual 394 
Assur. 1995;8(6):32-7. 395 
31. Avis M, Bond M, Arthur A. Satisfying solutions? A review of some unresolved issues in the 396 
measurement of patient satisfaction. J Adv Nurs. 1995;22(2):316-22. 397 
32. Carr-Hill RA. The measurement of patient satisfaction. J Public Health Med. 1992;14(3):236-398 
49. 399 
33. Borgers N, de Leeuw E, Hox J. Children as respondents in survey research: cognitive 400 
development and response quality 1. Bull Methodol Sociol. 2000;66(1):60-75. 401 
 402 




Figure legends 405 
Figure 1: Smart Track electronic monitoring device (image supplied by Adherium Limited, 406 







  414 
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Figure 2. Participant flow diagram for inclusion of participants in the clinical trial 415 
 416 
Figures 3a and b – Histograms depicting distribution of participant responses to acceptability 417 
questionnaire items 1 to 7  418 
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